CRUINT

What CRUINT does

CRUINT is the commercial identity of CRU Hungary Ltd. and its parent CRU Global Network, a hospital-embedded contract research organization (CRO) and clinical research site network headquartered in Göd, Hungary, with global headquarters in Singapore. Founded in 2007 as Hungary's first hospital-based clinical research unit for Phase II–III studies, the company operates dedicated Phase I units (first established in 2015, with the most recent opened in 2021) and conducts Phase I–IV clinical trials across pulmonology, cardiology, diabetology, rheumatology, gastroenterology, neurology, oncology, and other therapeutic areas. Its core differentiator is a worldwide-leading position in hepatic and renal impairment Phase I studies, enabled by access to unique Hungarian governmental patient registries and an organized hospital referral network that supports fast enrollment of hard-to-recruit special-population patients.

The company generates revenue through professional services fees charged to pharmaceutical sponsors for clinical trial conduct and CRO services, including regulatory services, medical writing, eCRF preparation, pharmacovigilance, data management/biostatistics, project management, and QP release/IMP management. It targets large-cap pharmaceutical enterprises as its primary customer segment and has served a diversified roster of global pharma sponsors including Pfizer, Novartis, Sanofi, AstraZeneca, AbbVie, Eli Lilly, BMS, Boehringer Ingelheim, Roche, GSK, Amgen, MSD, Janssen, UCB, Galapagos, and Chiesi. Pricing is contracted bilaterally with sponsors and is not publicly disclosed. CRUINT currently operates with approximately 43 full-time staff in Hungary plus 20+ part-time subcontractors and runs 35–40 new studies per year, having completed 300+ Phase I–III trials with more than 5,000 enrolled patients.

CRU Global has been actively scaling in 2023–2024, expanding into Central and Eastern Europe (Poland, Czech Republic, Slovakia, Croatia, Serbia) and South-East Asia (Singapore, Malaysia), opening new Phase I units in pulmonology, neurology, and oncology, and signing partnerships with QUINTA-ANALYTICA (bioanalytical) and GCP-Service International (German CRO). The company operates from offices in Hungary, Singapore, Malaysia, Germany, and the USA, positioning itself as a multi-region specialty CRO with deep hepatic/renal impairment expertise and growing exposure to oncology and CNS early-phase trials.

Name

CRUINT

Legal name

CRU Hungary Ltd.

Website

https://cruint.com

Company type

Private

Founded year

2007

Operating status

Operating

Headcount range

1–10 employees

Short description

CRUINT (CRU Hungary Ltd. / CRU Global Network) is a hospital-embedded CRO and Phase I–IV clinical research site network, headquartered in Hungary with global HQ in Singapore, serving global pharmaceutical sponsors with a specialty focus on hepatic and renal impairment studies across Europe and South-East Asia.

Ownership category

akta.pro rank

Product category

Clinical Research Organization (CRO) Services

NAICS

Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Clinical CROs (Phase I–IV) (HLAGAAAA)

akta.pro secondary industries

Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL), Patient Recruitment, Site Feasibility & Trial Enablement CROs (HLAGAAAI)

Keywords

• Clinical trial services
• Contract research organization
• Early phase studies
• Hepatic impairment trials
• Renal impairment studies

Headquarters

HQ city

Göd

HQ country

Hungary

HQ region

Europe

Offices13 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. CRO Services: Full spectrum of Contract Research Organization services including regulatory services, medical writing, eCRF preparation, pharmacovigilance, data management/biostatistics, project management, and QP release/IMP management
2. Clinical Research Site Services: Phase I-IV clinical trial conduct at CRU owned facilities, including early phase studies with healthy volunteers or special patient populations
3. Early Phase CRO Services: Basic CRO services for early phase projects including study design consultancy, protocol writing, ICF/PIC writing, eCRF preparation, final report, and data management/biostatistics

Go-to-market motion2 records

Distribution channels2 records

Marketing channels3 records

Core offering

CRUINT is a Contract Research Organization (CRO) and Clinical Research Site Network operating hospital-based clinical research units in Hungary and partner sites across Central and Eastern Europe and South-East Asia. It conducts Phase I-IV clinical trials for pharmaceutical and biotech sponsors, with deep specialization in early phase studies (First-in-Human, SAD/MAD, BA/BE, PK/PD, drug-drug interaction) and unique expertise in hepatic and renal impairment patient studies. End-to-end CRO services include regulatory affairs, medical writing, eCRF preparation, pharmacovigilance, data management/biostatistics, and project management.

Product overview

CRUINT operates as a clinical research organization offering a comprehensive portfolio of services through its network. The core offerings include Early Phase Studies (Phase I-II studies including FIH, SAD/MAD, BA/BE, PK/PD, and Drug-Drug interaction studies), Phase II-IV Clinical Trials Service, and CRO Services. CRU Global serves as the overarching professional CRO and Clinical Research Site Network spanning Europe and South-East Asia. The company specializes particularly in hepatic impairment and renal impairment studies, neurology (Alzheimer's, Epilepsy, Stroke), and pulmo-oncology. All services are supported by experienced staff, quality management systems, and regulatory expertise including CTIS submissions.

Differentiator

Problem solved

Functional benefit

Products and services

• Phase II-IV Clinical Trials Service Full-service Phase II-IV clinical trial conduct at CRU sites across pulmonology, cardiology, diabetology, lipidology, rheumatology, gastroenterology, infectology, gynecology, dermatology, and neurology therapeutic areas, for pharmaceutical and biotech sponsors.
• Early Phase Studies Comprehensive Phase I-II clinical trial services including Proof-of-Concept (POC), Adaptive design, First-in-Human (FIH), Single/Multiple Ascending Dose (SAD/MAD), Bioavailability/Bioequivalence (BA/BE), PK/PD studies, and Drug-Drug interaction studies, with particular specialization in hepatic and renal impairment patient populations.
• CRO Services

Quantifiable outcome

• Over 300 Phase I-III clinical trials conducted with more than 5,000 enrolled patients
• +3 more outcomes

Named customers16 records

Segments3 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered core.

• QUINTA-ANALYTICA (Conscio group)coreStrategic or Co-development Partner · 1 March 2024CRU Global signed an official collaboration agreement with QUINTA-ANALYTICA, a member of the Conscio group, solidifying their partnership in the fields of clinical trials and bioanalytical testing. The agreement was signed by Roman Grunt, CEO of Quinta-Analytica, and Peter Kovacs dr, CEO of CRU Global Network. The partnership combines expertise, knowledge, and capabilities of both companies to contribute to advancement of clinical trials in biotechnology and pharmaceutical industries.
• GCP-Service InternationalcoreStrategic or Co-development Partner · 1 March 2024GCP-Service International and CRUINT GLOBAL Consulting officially formed a partnership in Prague. GCP-Service is headquartered in Germany while CRU GLOBAL operates Phase I trial units in Hungary, Vietnam, and Ukraine with headquarters in Singapore. The collaboration marks a significant step towards global expansion of jointly conducted efficient and successful clinical trials. Signed by Andreas Beust, CEO of GCP-Service, and dr. Péter Kovács, CEO of CRU Global.

Scale indicators10 records

Recent moves10 records

Expansion highlights5 records

Broad incumbents

• SGS Health & Nutrition: SGS provides clinical research services including early-phase clinical trials through Phase I-IV at its clinical research unit in Belgium. Competes as a multi-region European-based CRO offering first-in-human and PK studies.
• PAREXEL International: PAREXEL is a global clinical research organization offering Phase I-IV trial services, biostatistics, and regulatory consulting. Competes for the same enterprise pharma sponsors served by CRU Global.
• Medpace: Medpace is a mid-to-large global CRO focused on Phase II-IV trials across multiple therapeutic areas. Competes for therapeutic-area trial work in pulmonology, cardiology, diabetology, and oncology where CRU also operates.
• ICON plc: ICON plc is a top-3 global CRO offering Phase I-IV clinical research, biometrics, and consulting. Competes for the same top-20 pharma sponsors that buy from CRU on early-phase and special-population studies.
• IQVIA: IQVIA is the largest global CRO offering full Phase I-IV services, real-world evidence, and technology. Competes with CRU Global on large RFPs and drives pricing benchmarks across the CRO industry.
• Eurofins Scientific: Eurofins operates Central Laboratory and clinical trial services for pharma and CRO customers. Its bioanalytical and central lab offerings overlap with CRU's PK/PD lab and biomarker laboratory services.
• Charles River Laboratories: Charles River provides early-discovery through Phase I CRO services plus CDMO capabilities. Its Research Models & Services and Discovery & Safety segments overlap with CRU's early-phase and special-population offerings.

Direct peers

• Celerion: Celerion is a clinical research organization that specializes in early-phase clinical studies, particularly First-in-Human, PK/PD, and special-population (hepatic/renal impairment) trials. Most direct competitor to CRUINT's niche of hospital-based Phase I studies for hepatic and renal impairment indications.
• Altasciences: Altasciences operates early-phase clinical research units in North America offering Phase I studies including FIH, SAD/MAD, and special-population studies. Comparable as a multi-site early-phase CRO with similar Phase I-first business model.
• Quotient Sciences: Quotient Sciences is an early-phase clinical and bioanalytical CRO offering FIH, SAD/MAD, BA/BE, and translational pharmaceutics. Comparable to CRU's Phase I unit capabilities including PK/PD and drug-drug interaction studies with integrated bioanalytical services.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CRUINT